@article{00fd851d658e462087585babe70022dc,
title = "CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function",
abstract = "CD4+ regulatory T (Treg) cells, dependent upon the transcription factor Foxp3, contribute to tumour immunosuppression but are also required for immune homeostasis. There is interest in developing therapies that selectively target the immunosuppressive function of Treg cells within tumours without disrupting their systemic anti-inflammatory function. High levels of expression of chemokine (C-C motif) receptor 8 (CCR8) discriminate Treg cells within tumours from those found in systemic lymphoid tissues. It has recently been proposed that disruption of CCR8 function using blocking anti-CCR8 antibodies results in reduced accumulation of Treg cells within tumours and disruption of their immunosuppressive function. Here, using Ccr8−/− mice, we show that CCR8 function is not required for Treg cell accumulation or immunosuppression in the context of syngeneic MC38 colorectal adenocarcinoma and B16 melanoma tumours. We observed high levels of CCR8 expression on tumour-infiltrating Treg cells which were abolished in Ccr8−/− mice. High levels of CCR8 marked cells with high levels of suppressive function. However, whereas systemic ablation of Treg cells resulted in strikingly diminished tumour burden, growth of subcutaneously implanted tumours was unaffected by systemic CCR8 loss. Consistently, we observed minimal impact of systemic CCR8 ablation on the frequency, phenotype and function of tumour-infiltrating Treg cells and conventional T (Tconv) function. These findings suggest that CCR8 is not required for Treg cell accumulation and immunosuppressive function within tumours and that depletion of CCR8+ Treg cells rather than blockade of CCR8 function is a more promising avenue for selective immunotherapy.",
keywords = "CCR8, CD4 T cells, CD8 T cells, Foxp3, Treg, cancer, immunotherapy",
author = "Whiteside, {Sarah K.} and Grant, {Francis M.} and Gyori, {David S.} and Conti, {Alberto G.} and Imianowski, {Charlotte J.} and Paula Kuo and Rabab Nasrallah and Firas Sadiyah and Lira, {Sergio A.} and Frank Tacke and Eil, {Robert L.} and Burton, {Oliver T.} and James Dooley and Adrian Liston and Klaus Okkenhaug and Jie Yang and Rahul Roychoudhuri",
note = "Funding Information: The research was supported by Wellcome Trust–Royal Society Fellowship 105663/Z/14/Z (R. Roychoudhuri); Biotechnology and Biological Sciences Research Council grants BB/N007794/1, BBS/E/B/000C0427 and BBS/E/B/000C0428; Cancer Research UK grant C52623/A22597; Medical Research Council grant MR/S024468/1; and Hungarian National Research, Development and Innovation Office Fund (NKFIH‐OTKA Grant No. FK132971 to DSG). Areg Funding Information: We thank Bernhard Moser of Cardiff University and David Withers of the University of Birmingham for ideas and discussion. The research was supported by the Wellcome Trust/Royal Society grant 105663/Z/14/Z, the UK Biotechnology and Biological Sciences Research Council grant BB/N007794/1, Cancer Research UK grant C52623/A22597, MRC grant MR/S024468/1 and Hungarian National Scientific Research Fund grant (NKFIH‐OTKA FK132971). We thank members of the Babraham Institute Biological Services Facility and University of Cambridge UBS Gurdon Facility for technical support with animal experiments and the members of the Flow Cytometry Core from the Babraham Institute and the Department of Pathology at the University of Cambridge. We thank members of the Roychoudhuri laboratory for sharing of reagents, protocols, ideas and discussion. Funding Information: The research was supported by Wellcome Trust?Royal Society Fellowship 105663/Z/14/Z (R. Roychoudhuri); Biotechnology and Biological Sciences Research Council grants BB/N007794/1, BBS/E/B/000C0427 and BBS/E/B/000C0428; Cancer Research UK grant C52623/A22597; Medical Research Council grant MR/S024468/1; and Hungarian National Research, Development and Innovation Office Fund (NKFIH-OTKA Grant No. FK132971 to DSG). We thank Bernhard Moser of Cardiff University and David Withers of the University of Birmingham for ideas and discussion. The research was supported by the Wellcome Trust/Royal Society grant 105663/Z/14/Z, the UK Biotechnology and Biological Sciences Research Council grant BB/N007794/1, Cancer Research UK grant C52623/A22597, MRC grant MR/S024468/1 and Hungarian National Scientific Research Fund grant (NKFIH-OTKA FK132971). We thank members of the Babraham Institute Biological Services Facility and University of Cambridge UBS Gurdon Facility for technical support with animal experiments and the members of the Flow Cytometry Core from the Babraham Institute and the Department of Pathology at the University of Cambridge. We thank members of the Roychoudhuri laboratory for sharing of reagents, protocols, ideas and discussion. Publisher Copyright: {\textcopyright} 2021 The Authors. Immunology published by John Wiley & Sons Ltd.",
year = "2021",
month = aug,
doi = "10.1111/imm.13337",
language = "English",
volume = "163",
pages = "512--520",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",
}